Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ruppert

Showing results (111-120 of 188) with videos related to

Pageof 19
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2015
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemiaJames S Blachly, Amy S Ruppert, Weiqiang Zhao, et al.
Leukemia Research|August 2, 2014
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaKami Maddocks, Amy S Ruppert, Rebekah Browning, et al.
Leukemia|October 8, 2015
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemiaK A Rogers, A S Ruppert, A Bingman, et al.
Oncotarget|January 18, 2015
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemiaKati Kämpjärvi, Tiina M Järvinen, Tuomas Heikkinen, et al.
Leukemia Research|July 23, 2013
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemiaDeborah M Stephens, Amy S Ruppert, Kami Maddocks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disordersThomas S Lin, Kristie A Blum, Diane Beth Fischer, et al.
Leukemia|July 25, 2020
Second cancer incidence in CLL patients receiving BTK inhibitorsDavid A Bond, Ying Huang, James L Fisher, et al.
Cancer Chemotherapy and Pharmacology|June 26, 2012
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanesMaryam B Lustberg, Shubham Pant, Amy S Ruppert, et al.
Oncotarget|April 24, 2016
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemiaTimothy L Chen, Nikhil Gupta, Amy Lehman, et al.
Blood|July 27, 2021
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinibAdam S Kittai, Cecelia Miller, Daniel Goldstein, et al.
Pageof 19

Showing results (111-120 of 188) with videos related to

Sort By:
Pageof 19
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2015
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemiaJames S Blachly, Amy S Ruppert, Weiqiang Zhao, et al.
Leukemia Research|August 2, 2014
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaKami Maddocks, Amy S Ruppert, Rebekah Browning, et al.
Leukemia|October 8, 2015
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemiaK A Rogers, A S Ruppert, A Bingman, et al.
Oncotarget|January 18, 2015
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemiaKati Kämpjärvi, Tiina M Järvinen, Tuomas Heikkinen, et al.
Leukemia Research|July 23, 2013
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemiaDeborah M Stephens, Amy S Ruppert, Kami Maddocks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disordersThomas S Lin, Kristie A Blum, Diane Beth Fischer, et al.
Leukemia|July 25, 2020
Second cancer incidence in CLL patients receiving BTK inhibitorsDavid A Bond, Ying Huang, James L Fisher, et al.
Cancer Chemotherapy and Pharmacology|June 26, 2012
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanesMaryam B Lustberg, Shubham Pant, Amy S Ruppert, et al.
Oncotarget|April 24, 2016
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemiaTimothy L Chen, Nikhil Gupta, Amy Lehman, et al.
Blood|July 27, 2021
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinibAdam S Kittai, Cecelia Miller, Daniel Goldstein, et al.
Pageof 19